Insider filing
Traded Apr 15 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 23, 2026 · Filed Mar 24, 2026
Viatris's See Remarks sold $284K of Viatris shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$283,539
Shares × reported transaction price
25 days after results of Feb 26, 2026, 45 days before results of May 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $13.29 on Mar 23, 2026, 83% above its 52-week low and 18% below its high, after a 9% drop over the previous 30 trading days
52-week range $7.26 (Apr 10, 2025) to $16.13 (Feb 11, 2026), 68% of the way up, from 251 adjusted closes. 30 trading days earlier: $14.58 on Feb 6, 2026. Describes the past only, not a forecast
RSI 35, 19% above its 200-day average, 7% under its 50-day average, 18% below the 52-week high, 20-day volatility 37% a year, against the S&P 500: −12 points over 1 month, +14 points over 3 months, +35 points over 6 months
From the adjusted closes up to Mar 23, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Aprepitant on Mar 5, 2026, 18 days before this trade.
Generic drug approved. Active ingredient: Aprepitant. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.0% | −0.2% | +1.2% |
| 30 days | +8.1% | +8.7% | −0.6% |
| 90 days | +16.7% | +11.7% | +5.0% |
| 180 days | +26.7% | +17.8% | +8.9% |
Past results only. Not a forecast.
Insider filing
Traded Apr 15 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Apr 15 · filed 1 day later
Routine share withholding; mechanical by default.
Insider filing
Traded Apr 15 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.